Compare WAT & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAT | ARCC |
|---|---|---|
| Founded | 1958 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance/Investors Services |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 15.0B |
| IPO Year | 1995 | 2004 |
| Metric | WAT | ARCC |
|---|---|---|
| Price | $394.93 | $21.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $382.14 | $22.50 |
| AVG Volume (30 Days) | 531.7K | ★ 4.0M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 9.13% |
| EPS Growth | ★ 3.82 | N/A |
| EPS | ★ 10.88 | 1.99 |
| Revenue | ★ $3,105,638,000.00 | $3,018,000,000.00 |
| Revenue This Year | $7.96 | $4.41 |
| Revenue Next Year | $6.32 | $5.64 |
| P/E Ratio | $36.30 | ★ $10.55 |
| Revenue Growth | ★ 6.90 | 2.72 |
| 52 Week Low | $275.05 | $18.26 |
| 52 Week High | $423.56 | $23.84 |
| Indicator | WAT | ARCC |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 66.29 |
| Support Level | $386.09 | $20.51 |
| Resistance Level | $403.80 | $20.77 |
| Average True Range (ATR) | 9.63 | 0.30 |
| MACD | -1.66 | 0.12 |
| Stochastic Oscillator | 53.55 | 95.60 |
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.